Avecho Biotechnology (ASX:AVE) completes pharmaceutical CBD capsule
- Avecho Biotechnology (AVE) has completed the composition and design of the dosage form of its cannabidiol soft-gel product
- The appointed manufacturer of the cannabidiol (CBD) product, Catalent, completed the capsules intended for registration with the TGA
- The CBD capsules will be used in Avecho’s upcoming clinical trial campaign, which includes phase one and a pivotal efficacy study
- The finalised composition will contain 75 milligrams of CBD per soft-gel capsule
- Production will start at a small scale to validate the manufacturing process and analytical methods
- The company is up 13.3 per cent, trading at 1.7 cents
